Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
3.010
-0.140 (-4.44%)
At close: Aug 28, 2026, 4:00 PM EDT
2.980
-0.030 (-1.00%)
After-hours: Aug 28, 2026, 6:56 PM EDT
Evaxion Revenue
Evaxion had revenue of $7.49M in the twelve months ending June 30, 2026, up 135.86% year-over-year. In the year 2025, Evaxion had annual revenue of $7.53M with 125.12% growth.
Revenue (ttm)
$7.49M
Revenue Growth
+135.86%
P/S Ratio
3.35
Revenue / Employee
$162,848
Employees
46
Market Cap
25.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.53M | 4.18M | 125.12% |
| Dec 31, 2024 | 3.34M | 3.27M | 4,480.82% |
| Dec 31, 2023 | 73.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
EVAX News
- 10 days ago - Evaxion Earnings Call Transcript: Q2 2026 - Transcripts
- 10 days ago - Evaxion Earnings release: Q2 2026 - Filings
- 10 days ago - Evaxion Slides: Q2 2026 - Filings
- 10 days ago - Evaxion announces business update and second quarter 2026 financial results - GlobeNewsWire
- 13 days ago - Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program - GlobeNewsWire
- 16 days ago - Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 - GlobeNewsWire
- 20 days ago - Merck discloses 1.21M share holding in Evaxion Biotech - TheFly
- 6 weeks ago - Evaxion Biotech to present EVX-01 clinical efficacy data at ESMO - TheFly